stoxline Quote Chart Rank Option Currency Glossary
  
Vivos Therapeutics, Inc. (VVOS)
0.0569  -0.019 (-25.13%)    11-19 16:00
Open: 0.0737
High: 0.0737
Volume: 4,380,627
  
Pre. Close: 0.076
Low: 0.0559
Market Cap: 1(M)
Technical analysis
2026-11-19 4:39:19 PM
Short term     
Mid term     
Targets 6-month :  0.12 1-year :  0.16
Resists First :  0.11 Second :  0.14
Pivot price 0.09
Supports First :  0.05 Second :  0.04
MAs MA(5) :  0.07 MA(20) :  0.1
MA(100) :  0.23 MA(250) :  0.9
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  8.7 D(3) :  14.7
RSI RSI(14): 19.6
52-week High :  2.69 Low :  0.05
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VVOS ] has closed below the lower bollinger band by 11.0%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.07 - 0.07 0.07 - 0.07
Low: 0.05 - 0.06 0.06 - 0.06
Close: 0.06 - 0.06 0.06 - 0.06
Company Description

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Headline News

Mon, 16 Nov 2026
Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

Mon, 16 Nov 2026
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update - Quantisnow

Mon, 16 Nov 2026
Vivos Therapeutics, Inc. (VVOS) Q3 FY2026 earnings call transcript - Yahoo Finance

Mon, 26 Oct 2026
Ralph Elias Green receives 12,000 Vivos Therapeutics (VVOS) options with a $0.18 exercise price. - Stock Titan

Tue, 18 Aug 2026
Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... - Yahoo Finance

Mon, 17 Aug 2026
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 34 (M)
Held by Insiders 1.901e+007 (%)
Held by Institutions 11.5 (%)
Shares Short 1,630 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.076e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -121.8 %
Operating Margin -93.7 %
Return on Assets (ttm) -56.2 %
Return on Equity (ttm) -8 %
Qtrly Rev. Growth 2.09e+007 %
Gross Profit (p.s.) 5.53
Sales Per Share 92.89
EBITDA (p.s.) 2.05397e+006
Qtrly Earnings Growth -1.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -1.06
Stock Dividends
Dividend 0
Forward Dividend 2.36e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android